In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Crispr Therapeutics AG, with a price target of $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mitchell Kapoor has given his Buy rating due to a combination of factors influencing Crispr Therapeutics AG’s outlook. The company has demonstrated a significant increase in CASGEVY sales, with a notable 114% rise in the second quarter of 2025 compared to the first quarter. This growth is attributed to a snowball-like effect in patient adoption, as more patients are opting for treatment following the experiences of others.
Additionally, Crispr Therapeutics has expanded its global reach by activating 75 authorized treatment centers, which is expected to further drive growth. Despite a wider net loss than anticipated, the company maintains a strong cash position, providing operational stability into 2027. The inclusion of CTX310 in their model, with potential peak revenues of $4 billion, adds another promising avenue for growth. These factors collectively support Kapoor’s decision to reiterate a Buy rating and increase the 12-month price target to $80.
In another report released on August 5, Chardan Capital also maintained a Buy rating on the stock with a $82.00 price target.